Skip to main content
Top
Published in: American Journal of Clinical Dermatology 3/2004

01-06-2004 | Therapy in Practice

Optimal Management of Recalcitrant Disorders of Hyperpigmentation in Dark-Skinned Patients

Authors: Alexander J. Stratigos, Dr Andreas D. Katsambas

Published in: American Journal of Clinical Dermatology | Issue 3/2004

Login to get access

Abstract

Alterations in skin pigmentation may often have a dramatic expression in individuals with a dark skin complexion and can be a source of significant emotional distress in these individuals. Hyperpigmented disorders such as melanosis (melasma), post-inflammatory hyperpigmentation, drug-induced hyperpigmentation, and erythema dyschromicum perstans tend to have a prolonged course and, in many cases, are refractory to treatment, further contributing to the psychological impairment of the affected patients. Melanosis, is a common form of facial pigmentation attributable to sunlight and hormonal factors. A range of treatment modalities, such as depigmenting agents, topical retinoids, and chemical peels in conjunction with rigorous sun protection, can improve the melanosis but the condition usually recurs. Combination regimens, including frequent applications of superficial- and medium-depth chemical peels, appear to be particularly effective and well tolerated in dark-skinned patients with melanosis. Post-inflammatory hyperpigmentation is the result of excess pigment deposition following an inflammatory skin disorder. Topical tretinoin, hydroquinone, azelaic acid, kojic acid, and glycolic acid peels have been employed with variable degrees of success. Drug-induced pigmentation is a frequent cause of acquired hypermelanosis, its clinical expression depending on the triggering molecule and the underlying pathogenetic mechanism. Identifying and discontinuing the offending agent is the main approach in this condition, although, recent reports have demonstrated the efficacy of Q-switched lasers in accelerating the pigment removal. Erythema dischromicum perstans is a characteristic dermal pigmentation occurring mainly in dark-skinned individuals. Immunomodulating agents, such as clofazimine and dapsone have been shown to lighten this disorder, although, the exact mode of action is not clear.
Literature
1.
go back to reference Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol 2002; 46 (Suppl.2): S41–62CrossRef Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol 2002; 46 (Suppl.2): S41–62CrossRef
2.
go back to reference O’Brien TJ, Dyall-Smith D, Hall AP. Melasma of the forearms. Austral J Dermatol 1997; 38: 35–7CrossRef O’Brien TJ, Dyall-Smith D, Hall AP. Melasma of the forearms. Austral J Dermatol 1997; 38: 35–7CrossRef
3.
4.
go back to reference Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 1981; 4: 698–710PubMedCrossRef Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 1981; 4: 698–710PubMedCrossRef
5.
go back to reference Taylor SC. Epidemiology of skin diseases in ethnic populations. Dermatol Clin 2003; 21 (4): 601–7PubMedCrossRef Taylor SC. Epidemiology of skin diseases in ethnic populations. Dermatol Clin 2003; 21 (4): 601–7PubMedCrossRef
6.
go back to reference Kimbrough-Green CK, Griffiths CEM, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in Black patients: a vehicle-controlled clinical trial. Arch Dermatol 1994; 130: 727–33PubMedCrossRef Kimbrough-Green CK, Griffiths CEM, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in Black patients: a vehicle-controlled clinical trial. Arch Dermatol 1994; 130: 727–33PubMedCrossRef
7.
go back to reference Resnik S. Melasma induced by oral contraceptive drugs. JAMA 1967; 199: 95–9CrossRef Resnik S. Melasma induced by oral contraceptive drugs. JAMA 1967; 199: 95–9CrossRef
8.
go back to reference Johnston GA, Sviland L, McLelland J. Melasma of the arms associated with hormone replacement therapy [letter]. Br J Dermatol 1998; 139: 932PubMedCrossRef Johnston GA, Sviland L, McLelland J. Melasma of the arms associated with hormone replacement therapy [letter]. Br J Dermatol 1998; 139: 932PubMedCrossRef
9.
go back to reference Hassan I, Kaur I, Sialy R, et al. Hormonal milieu in the maintenance of melasma in fertile women. J Dermatol 1998; 25: 510–2PubMed Hassan I, Kaur I, Sialy R, et al. Hormonal milieu in the maintenance of melasma in fertile women. J Dermatol 1998; 25: 510–2PubMed
10.
go back to reference Katsambas AD, Stratigos AJ. Depigmenting and bleaching agents: coping with hyperpigmentation. Clin Dermatol 2001; 19: 483–8PubMedCrossRef Katsambas AD, Stratigos AJ. Depigmenting and bleaching agents: coping with hyperpigmentation. Clin Dermatol 2001; 19: 483–8PubMedCrossRef
11.
go back to reference Kramer KE, Lopez A, Stefanato CM, et al. Exogenous ochronosis. J Am Acad Dermatol 2000; 42: 869–71PubMedCrossRef Kramer KE, Lopez A, Stefanato CM, et al. Exogenous ochronosis. J Am Acad Dermatol 2000; 42: 869–71PubMedCrossRef
12.
go back to reference Levin CY, Maibach H. Exogenous ochronosis: an update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2: 213–7PubMedCrossRef Levin CY, Maibach H. Exogenous ochronosis: an update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2: 213–7PubMedCrossRef
13.
go back to reference Perez-Bernal A, Munoz-Perez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol 2000; 1 (5): 261–8PubMedCrossRef Perez-Bernal A, Munoz-Perez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol 2000; 1 (5): 261–8PubMedCrossRef
14.
15.
go back to reference Kang WH, Chun SC, Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoin acid, hydroquinone and hydrocortisone): clinical and histological studies. J Dermatol 1998; 25: 587–96PubMed Kang WH, Chun SC, Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoin acid, hydroquinone and hydrocortisone): clinical and histological studies. J Dermatol 1998; 25: 587–96PubMed
16.
go back to reference Yoshimura K, Harii K, Aoyama T, et al. A new bleaching protocol for hyperpigmented skin lesions with a high concentration of all-trans-retinoic acid aqueous gel. Aesthetic Plast Surg 1999; 23: 285–91PubMedCrossRef Yoshimura K, Harii K, Aoyama T, et al. A new bleaching protocol for hyperpigmented skin lesions with a high concentration of all-trans-retinoic acid aqueous gel. Aesthetic Plast Surg 1999; 23: 285–91PubMedCrossRef
17.
go back to reference Tadaki T, Watanabe M, Kumasaka K, et al. The effect of topical tretinoin on the photodamaged skin of Japanese. Tohoku J Exp Med 1993; 169: 131–9PubMedCrossRef Tadaki T, Watanabe M, Kumasaka K, et al. The effect of topical tretinoin on the photodamaged skin of Japanese. Tohoku J Exp Med 1993; 169: 131–9PubMedCrossRef
18.
go back to reference Griffiths CEM, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma: a vehicle-controlled, clinical trial. Br J Dermatol 1993; 129: 415–21PubMedCrossRef Griffiths CEM, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma: a vehicle-controlled, clinical trial. Br J Dermatol 1993; 129: 415–21PubMedCrossRef
19.
go back to reference Balina LM, Graupe K. The treatment of melasma: 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 1991; 30: 893–5PubMedCrossRef Balina LM, Graupe K. The treatment of melasma: 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 1991; 30: 893–5PubMedCrossRef
20.
go back to reference Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl. (Stockh) 1989; 143: 58–61 Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl. (Stockh) 1989; 143: 58–61
21.
go back to reference Garcia A, Fulton JE. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg 1999; 22: 443–7CrossRef Garcia A, Fulton JE. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg 1999; 22: 443–7CrossRef
22.
go back to reference Jimbow K. N-acetyl-4–5cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma. Arch Dermatol 1991; 127: 1528–34PubMedCrossRef Jimbow K. N-acetyl-4–5cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma. Arch Dermatol 1991; 127: 1528–34PubMedCrossRef
23.
go back to reference Lim JTE, Tham SN. Glycolic acid peels in the treatment of melasma among Asian women. Dermatol Surg 1997; 23: 177–9PubMedCrossRef Lim JTE, Tham SN. Glycolic acid peels in the treatment of melasma among Asian women. Dermatol Surg 1997; 23: 177–9PubMedCrossRef
24.
go back to reference Sarkar R, Kaur C, Bhalla M, et al. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg 2002; 28: 828–32PubMedCrossRef Sarkar R, Kaur C, Bhalla M, et al. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg 2002; 28: 828–32PubMedCrossRef
25.
go back to reference Hurley ME, Guevara IL, Gonzales RM, et al. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol 2002; 138: 1578–82PubMedCrossRef Hurley ME, Guevara IL, Gonzales RM, et al. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol 2002; 138: 1578–82PubMedCrossRef
26.
go back to reference Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg 1999; 25: 18–22PubMedCrossRef Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg 1999; 25: 18–22PubMedCrossRef
27.
go back to reference Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and post-inflammatory hyperpigmentation by Q-switched laser. J Dermatol Surg Oncol 1994; 20: 592–7PubMed Taylor CR, Anderson RR. Ineffective treatment of refractory melasma and post-inflammatory hyperpigmentation by Q-switched laser. J Dermatol Surg Oncol 1994; 20: 592–7PubMed
28.
go back to reference Manaloto RM, Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg 1999; 25: 121–3PubMedCrossRef Manaloto RM, Alster T. Erbium:YAG laser resurfacing for refractory melasma. Dermatol Surg 1999; 25: 121–3PubMedCrossRef
29.
go back to reference Nouri K, Bowes L, Chartier T, et al. Combination treatment of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser: a pilot study. Dermatol Surg 1999; 25: 494–7PubMedCrossRef Nouri K, Bowes L, Chartier T, et al. Combination treatment of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser: a pilot study. Dermatol Surg 1999; 25: 494–7PubMedCrossRef
30.
go back to reference Nordlund JJ. Postinflammatory hyperpigmentation. Dermatol Clin 1988; 6: 185–92PubMed Nordlund JJ. Postinflammatory hyperpigmentation. Dermatol Clin 1988; 6: 185–92PubMed
31.
go back to reference Ruiz-Maldonado R, Orozco-Covarrubias ML. Postinflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg 1997 Mar; 16 (1): 36–43PubMedCrossRef Ruiz-Maldonado R, Orozco-Covarrubias ML. Postinflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg 1997 Mar; 16 (1): 36–43PubMedCrossRef
32.
go back to reference Bulengo-Ransby SM, Griffiths CEM, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in Black patients. N Engl J Med 1993; 328: 1438–43PubMedCrossRef Bulengo-Ransby SM, Griffiths CEM, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in Black patients. N Engl J Med 1993; 328: 1438–43PubMedCrossRef
33.
go back to reference Burns RL, Prevost-Blank PL, Lawry MA, et al. Glycolic acid peels for postinflammatory hyperpigmentation in Black patients. Dermatol Surg 1997; 23: 171–5PubMedCrossRef Burns RL, Prevost-Blank PL, Lawry MA, et al. Glycolic acid peels for postinflammatory hyperpigmentation in Black patients. Dermatol Surg 1997; 23: 171–5PubMedCrossRef
34.
go back to reference Watanabe S, Brorson S, Dalickas G, et al. Comparative studies of femtosecond to microsecond laser pulses on selective pigmented cell injury in skin. Photochem Photobiol 1991; 53: 757–62PubMed Watanabe S, Brorson S, Dalickas G, et al. Comparative studies of femtosecond to microsecond laser pulses on selective pigmented cell injury in skin. Photochem Photobiol 1991; 53: 757–62PubMed
35.
go back to reference Dereure O. Drug-induced skin pigmentation: epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001; 2: 253–63PubMedCrossRef Dereure O. Drug-induced skin pigmentation: epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001; 2: 253–63PubMedCrossRef
37.
go back to reference Argenyi ZB, Finelli L, Bergfeld WF, et al. Minocycline-related cutaneous hyperpigmentation as demonstrated by light microscopy, electron microscopy and X-Ray energy spectroscopy. J Cutan Pathol 1987; 14: 176–80PubMedCrossRef Argenyi ZB, Finelli L, Bergfeld WF, et al. Minocycline-related cutaneous hyperpigmentation as demonstrated by light microscopy, electron microscopy and X-Ray energy spectroscopy. J Cutan Pathol 1987; 14: 176–80PubMedCrossRef
38.
go back to reference Odom RB, James WD, Berger TG. Contact dermatitis and drug eruptions. In: Odom RB, James WD, Berger TG, et al., editors. Andrew’s diseases of the skin: clinical dermatology. 9th ed. Philadephia (PA): WB Saunders Co., 2000: 133–4 Odom RB, James WD, Berger TG. Contact dermatitis and drug eruptions. In: Odom RB, James WD, Berger TG, et al., editors. Andrew’s diseases of the skin: clinical dermatology. 9th ed. Philadephia (PA): WB Saunders Co., 2000: 133–4
39.
go back to reference Sokol RJ, Lichtenstein PK, Farrell MK. Quinacrine hydrochloride-induced yellow discoloration of the skin in children. Pediatrics 1982; 69 (2): 232–3PubMed Sokol RJ, Lichtenstein PK, Farrell MK. Quinacrine hydrochloride-induced yellow discoloration of the skin in children. Pediatrics 1982; 69 (2): 232–3PubMed
40.
go back to reference Waitzer S, Butany J, From L, et al. Cutaneous ultrastructural changes and photosensitivity associated with amiodarone therapy. J Am Acad Dermatol 1987; 16 (4): 779–87PubMedCrossRef Waitzer S, Butany J, From L, et al. Cutaneous ultrastructural changes and photosensitivity associated with amiodarone therapy. J Am Acad Dermatol 1987; 16 (4): 779–87PubMedCrossRef
41.
go back to reference Job CK, Yoder L, Jacobson RR, et al. Skin pigmentation from clofazimine therapy in leprosy patients: a reappraisal. J Am Acad Dermatol 1990; 23 (2): 236–41PubMedCrossRef Job CK, Yoder L, Jacobson RR, et al. Skin pigmentation from clofazimine therapy in leprosy patients: a reappraisal. J Am Acad Dermatol 1990; 23 (2): 236–41PubMedCrossRef
42.
go back to reference Collins P, Cotterill JA. Minocycline-induced pigmentation resolves after treatment with the Q-switched ruby laser. Br J Dermatol 1996; 135: 317–9PubMedCrossRef Collins P, Cotterill JA. Minocycline-induced pigmentation resolves after treatment with the Q-switched ruby laser. Br J Dermatol 1996; 135: 317–9PubMedCrossRef
43.
go back to reference Tsao H, Busam K, Barnhill RL, et al. Treatment of minocycline-induced hyperpigmentation with the Q-switched ruby laser. Arch Dermatol 1996; 132: 1250–1PubMedCrossRef Tsao H, Busam K, Barnhill RL, et al. Treatment of minocycline-induced hyperpigmentation with the Q-switched ruby laser. Arch Dermatol 1996; 132: 1250–1PubMedCrossRef
44.
go back to reference Becker-Wegerich PM, Kuhn A, Malek L, et al. Treatment of nonmelanotic hyperpigmentation with the Q-switched ruby laser. J Am Acad Dermatol 2000; 43: 272–4PubMedCrossRef Becker-Wegerich PM, Kuhn A, Malek L, et al. Treatment of nonmelanotic hyperpigmentation with the Q-switched ruby laser. J Am Acad Dermatol 2000; 43: 272–4PubMedCrossRef
45.
go back to reference Karrer S, Hohenleutner U, Szeimies RM, et al. Amiodarone-induced pigmentation resolves after treatment with the Q-switched ruby laser. Arch Dermatol 1999; 135: 251–3PubMedCrossRef Karrer S, Hohenleutner U, Szeimies RM, et al. Amiodarone-induced pigmentation resolves after treatment with the Q-switched ruby laser. Arch Dermatol 1999; 135: 251–3PubMedCrossRef
46.
go back to reference Ramirez CO. The ashy dermatosis (erythema dyschromicum perstan: epidemiological study and report of 139 cases. Cutis 1967; 3: 244–7 Ramirez CO. The ashy dermatosis (erythema dyschromicum perstan: epidemiological study and report of 139 cases. Cutis 1967; 3: 244–7
47.
go back to reference Ing EB, Buncic JR, Weiser BA, et al. Periorbital hyperpigmentation and erythema dischromicum perstans. Can J Ophthalmol 1992; 27: 353–5PubMed Ing EB, Buncic JR, Weiser BA, et al. Periorbital hyperpigmentation and erythema dischromicum perstans. Can J Ophthalmol 1992; 27: 353–5PubMed
48.
go back to reference Baranda L, Torres-Alvarez B, Cortes-Franco R, et al. Involvement of cell adhesions and activation molecules in the pathogenesis of erythema dischromicum perstans (ashy dermatitis): the effect of clofazimine therapy. Arch Dermatol 1997; 133: 325–9PubMedCrossRef Baranda L, Torres-Alvarez B, Cortes-Franco R, et al. Involvement of cell adhesions and activation molecules in the pathogenesis of erythema dischromicum perstans (ashy dermatitis): the effect of clofazimine therapy. Arch Dermatol 1997; 133: 325–9PubMedCrossRef
49.
go back to reference Kontochristopoulos G, Stavropoulos P, Panteleos D, et al. Erythema dischromicum perstans: response to dapsone therapy. Int J Dermatol 1998; 37: 790–9CrossRef Kontochristopoulos G, Stavropoulos P, Panteleos D, et al. Erythema dischromicum perstans: response to dapsone therapy. Int J Dermatol 1998; 37: 790–9CrossRef
Metadata
Title
Optimal Management of Recalcitrant Disorders of Hyperpigmentation in Dark-Skinned Patients
Authors
Alexander J. Stratigos
Dr Andreas D. Katsambas
Publication date
01-06-2004
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 3/2004
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200405030-00004

Other articles of this Issue 3/2004

American Journal of Clinical Dermatology 3/2004 Go to the issue